Skip to main content
TipRanks
Go Ultimate75% OFF

Inovio Pharmaceuticals (INO) Stock Price & Analysis

6,106 Followers

INO Stock Chart & Stats

$1.71$0.02(1.18%)
At close: 4:00 PM EST
$0.5$1$1.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.63 - $1.79
52-Week Range
$0.56 - $2.72
Previous Close
$1.69
Volume
N/A
Average Volume (3M)
19.60M
Market Cap
$320.29M
Enterprise Value
$79.25M
Total Cash (Recent Filing)
$48.36M
Total Debt (Recent Filing)
$7.28M
Price to Earnings (P/E)
―
Beta
0.83
Next Earnings
Mar 02, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

First Approved Product

FDA approval moves Inovio from a development-stage biotechnology company toward commercial operations and validates its DNA medicine and CELLECTRA delivery platform. It creates an approved product base from which the company can pursue U.S. sales, additional indications, and international expansion.

Durable Clinical Benefit

Reported reductions in surgery, durable benefit through year three, and supportive immune-response findings strengthen the product’s clinical differentiation. If confirmed, this profile could support sustained physician adoption and improve the durability of VOCERYQ’s commercial opportunity.

Launch Readiness And Market Reach

The planned field organization, payer-support capabilities, manufacturing capacity, and identified RRP population provide a defined path to commercialization. Coverage focused on major institutions and integrated networks should help the company reach concentrated patient populations efficiently after launch.

Bears Say

Confirmatory Approval Risk

Accelerated approval leaves the product’s long-term regulatory status dependent on additional evidence. The required study must enroll patients and track surgical outcomes for at least three years, creating execution, timing, and potential approval risk that could affect the commercial opportunity.

Escalating Cash Burn

Persistent and worsening cash consumption means Inovio must fund operations while simultaneously building its commercial organization. Continued negative cash flow can restrict investment flexibility and increase reliance on financing before product revenue becomes sufficiently established.

Negative Equity And Financing Risk

Deeply negative equity signals a materially weakened balance sheet after prolonged losses and limits the company’s ability to absorb further operating shortfalls. Financing may therefore be needed on unfavorable terms, increasing dilution risk as Inovio funds launch and development activities.

Inovio Pharmaceuticals News

INO FAQ

What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $0.56 and its highest was $2.72 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $320.29M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 102 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Nov 10, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.207 by -$0.293.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a monthly dividend of $0.069 which represents an annual dividend yield of ―. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.13.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 187,306,880 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.207. Following the earnings report the stock price went up 1.724%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Hedge funds hold Inovio Pharmaceuticals shares: the largest hedge-fund position in Inovio Pharmaceuticals is 72,418,416 shares, and hedge funds increased their holdings by 7.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology